Ionis Slashes Key Drug Revenue Outlook by 50%, Overshadowing Otherwise Solid Earnings

Ionis Slashes Key Drug Revenue Outlook by 50%, Overshadowing Otherwise Solid Earnings

来源:Barrons发布于 2026-11-09

Shares of Ionis Pharmaceuticals sink after it slashes full-year revenue guidance for one of its flagship drugs.

相关标的:IONS

本文内容来自外部来源,点击「继续访问」将跳转到原始发布站点。